Evidence map›Paper›PMID 34483912›Full record

ArticleFrontiers in pharmacology2021

Galectin-3 Deletion Reduces LPS and Acute Colitis-Induced Pro-Inflammatory Microglial Activation in the Ventral Mesencephalon.

Ana M Espinosa-Oliva, Pablo García-Miranda, Isabel María Alonso-Bellido, Ana E Carvajal, Melania González-Rodríguez, Alejandro Carrillo-Jiménez, Arturo J Temblador, Manuel Felices-Navarro, Irene García-Domínguez, María Angustias Roca-Ceballos and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Regulation of microglia polarization after cerebral ischemia.Frontiers in cellular neuroscience · 2023
    Review
  7. Article
  8. Inflammatory Animal Models of Parkinson's Disease.Journal of Parkinson's disease · 2022
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Ana M Espinosa-OlivaInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocío/CSIC/Universidad de Sevilla, Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad de, Sevilla, Spain.
Pablo García-MirandaDepartamento de Fisiología, Facultad de Farmacia, Universidad de Sevilla, Sevilla, Spain.
Isabel María Alonso-BellidoInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocío/CSIC/Universidad de Sevilla, Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad de, Sevilla, Spain.
Ana E CarvajalDepartamento de Fisiología, Facultad de Farmacia, Universidad de Sevilla, Sevilla, Spain.
Melania González-RodríguezNeuroplasticity and Neurodegeneration Laboratory, Ciudad Real Medical School, CRIB, Universidad de Castilla-La Mancha, Ciudad Real, Spain.
Alejandro Carrillo-JiménezInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocío/CSIC/Universidad de Sevilla, Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad de, Sevilla, Spain.
Arturo J TembladorLaboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Leuven, Belgium.
Manuel Felices-NavarroInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocío/CSIC/Universidad de Sevilla, Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad de, Sevilla, Spain.
Irene García-DomínguezInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocío/CSIC/Universidad de Sevilla, Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad de, Sevilla, Spain.
María Angustias Roca-CeballosInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocío/CSIC/Universidad de Sevilla, Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad de, Sevilla, Spain.
María D Vázquez-CarreteroDepartamento de Fisiología, Facultad de Farmacia, Universidad de Sevilla, Sevilla, Spain.
Juan García-RevillaInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocío/CSIC/Universidad de Sevilla, Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad de, Sevilla, Spain.
Marti SantiagoInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocío/CSIC/Universidad de Sevilla, Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad de, Sevilla, Spain.
María J PeralDepartamento de Fisiología, Facultad de Farmacia, Universidad de Sevilla, Sevilla, Spain.
José Luis VeneroInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocío/CSIC/Universidad de Sevilla, Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad de, Sevilla, Spain.
Rocío M de PablosInstituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocío/CSIC/Universidad de Sevilla, Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad de, Sevilla, Spain.
Universidad de Sevilla · ESHospital Universitario Virgen del Rocío · ESInstituto de Biomedicina de Sevilla · ESRega Institute for Medical Research · BEUniversity of Castilla-La Mancha · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease is a highly prevalent neurological disorder for which there is currently no cure. Therefore, the knowledge of risk factors as well as the development of new putative molecular targets is mandatory. In this sense, peripheral inflammation, especially the originated in the colon, is emerging as a predisposing factor for suffering this disease. We have largely studied the pleiotropic roles of galectin-3 in driving microglia-associated immune responses. However, studies aimed at elucidating the role of galectin-3 in peripheral inflammation in terms of microglia polarization are lacking. To achieve this, we have evaluated the effect of galectin-3 deletion in two different models of acute peripheral inflammation: intraperitoneal injection of lipopolysaccharide or gut inflammation induced by oral administration of dextran sodium sulfate. We found that under peripheral inflammation the number of microglial cells and the expression levels of pro-inflammatory mediators take place specifically in the dopaminergic system, thus supporting causative links between Parkinson's disease and peripheral inflammation. Absence of galectin-3 highly reduced neuroinflammation in both models, suggesting an important central regulatory role of galectin-3 in driving microglial activation provoked by the peripheral inflammation. Thus, modulation of galectin-3 function emerges as a promising strategy to minimize undesired microglia polarization states.

Indexed as

galectin-3microglianeuroinflammationParkinson’s diseaseperipheral inflammation

Identifiers

PMID34483912
PMCPMC8416309
OpenAlexW3193806271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.